Overview

GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )

Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study will be a multicentre prospective randomized trial to assess the percentage of patients with IBD who, after stopping anti-TNF treatment, have sustained clinical remission at one year compared to those in which the treatment is continued at stable doses
Phase:
Phase 4
Details
Lead Sponsor:
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Treatments:
Adalimumab
Infliximab
Pharmaceutical Solutions